BT 11

Next Previous
Drug Profile

BT 11

Alternative Names: BT-11

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Landos Biopharma
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease; Ulcerative colitis

Most Recent Events

  • 19 Dec 2017 Landos Biopharma plans phase Ia, IIa and III clinical trials for Crohn’s disease in 2018
  • 03 Oct 2017 Landos Biopharma has patent protection for BT 11 in USA (Landos Biopharma, September 2017)
  • 03 Oct 2017 Preclinical pharmacodynamics data in Crohn's disease released by Landos Biopharma (Landos Biopharma pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top